• Explore /
  • Poster
  • / A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours.

A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours.

Abstract Poster

Authors

null

Rosalind Margaret Glasspool

Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Rosalind Margaret Glasspool , Sarah Patricia Blagden , Michelle Lockley , James Paul , Carol Hopkins , Fiona Thomson , Jennifer Brown , Ricardo Fernandes , Nivea Douglas , Chantevy Pou , Aishah Hanif , Craig Campbell , Pratik S. Multani , Trevor Tucker , Iain A. McNeish , T.R. Jeffry Evans

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Small Molecules

Clinical Trial Registration Number

ISRCTN15903698

Citation

J Clin Oncol 35, 2017 (suppl; abstr 2594)

DOI

10.1200/JCO.2017.35.15_suppl.2594

Abstract #

2594

Poster Bd #

86

Abstract Disclosures

Similar Posters

First Author: Carlos A. Gomez-Roca

First Author: Devalingam Mahalingam

Poster

2012 ASCO Annual Meeting

Phase I study of oral rigosertib in patients with advanced solid tumors.

Phase I study of oral rigosertib in patients with advanced solid tumors.

First Author: Daniel W. Bowles

First Author: Chia-Chi Lin